Definium Therapeutics rises after anxiety disorder drug meets late-stage trial goal
DFTX•Stock performance
As of the last close, DFTX was up 205.5% year to date.
Trial results and safety findings
Patients on the drug had an 11.6-point drop on a standard anxiety rating scale at week 12, compared with a 6.2-point drop for those on a placebo, Definium said.
Most side effects were mild to moderate and temporary, occurring mainly on the day of dosing, with no increase in suicidal thoughts, the company said.
Shares rise after late-stage anxiety trial meets goal
Shares of biotech firm Definium Therapeutics DFTX.O rose 22.2% to $50.01 premarket after the company said its LSD-based experimental pill significantly reduced anxiety symptoms in adults with generalized anxiety disorder, or GAD, in a late-stage study, meeting the trial's main goal.
